Let’s proceed with further insights from each country presented in the Access Briefing Q2 – this week: England UK compiled by Cogentia.

Based on the NICE decisions, there were several other exciting results.

Here’s what stood out in Q2 👇

 

England

Highlights:

🏛️ NICE published 27 guidance documents. 3 of these were for the same product, tislelizumab.

🧬 Olipudase alfa was the second ever Highly-specialised technology (HST)-routed technology to not be recommended for reimbursement, despite an appeal.

 

The stats:

✅ 19 Recommended

⏰️ 6 Terminated appraisal

❌ 2 Not-recommended

 

Wales

Highlights:

🏛️ AWMSG published 10 assessments. 13 appraisals were excluded from AWMSG assessment, as they have been recommended by NICE, with AWMSG following NICE guidance where it is positive.

☝️ 5 of the 7 recommendations related to off-label use of medicines. Given AWMSG’s remit is limited to medicines not recommended by NICE, this allows them more time & capacity to consider broader use of medicines outside of their approved indication.

 

The stats:

✅ 7 Recommended

🔎 3 Under consideration

 

Scotland

Highlights:

🏛️ SMC published 21 assessments.

🧬 Initial assessment of the evidence for exagamglogene autotemcel: Casgevy® can be prescribed within the ultra-orphan pathway while further evidence on its effectiveness is generated.

🚫 SMC follows NICE in rejecting Kisunla for Alzheimer's after Eli Lilly "did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC".

 

The stats:

✅ 8 Accepted

🔒 7 Accepted for restricted use

🔎 1 Accepted with further data collection

❌ 5 Not-recommended

 

Northern Ireland

✅ Northern Ireland follows NICE guidance.

 

📝 Register here to receive the latest and upcoming issues of the complete  Access Briefing with HTA insights from 14 countries, compiled by 9 partners of our network 👉 https://forms.office.com/e/Jt8bPmVkdJ